Shih‐Ting Chiu
Papers
1
Total Citations
9
H-Index
1
About
Dr. Shih‐Ting Chiu is a urological researcher whose work focuses on improving the preoperative risk stratification of prostate cancer. Her primary research area involves the clinical application of novel biomarkers, specifically the prostate health index (PHI) and its derivative, %p2PSA, to predict aggressive pathological outcomes. In her most cited study, published in 2020, Dr. Chiu evaluated the predictive accuracy of these markers in a cohort of 91 patients with organ-confined prostate cancer undergoing robot-assisted radical prostatectomy. Her findings demonstrated that %p2PSA and PHI could serve as valuable, non-invasive tools for identifying patients at higher risk for adverse pathology, potentially guiding more personalized surgical decisions. This work, which has garnered 9 citations, contributes to the growing body of evidence supporting the use of these biomarkers beyond initial diagnosis. Dr. Chiu’s research bridges the gap between laboratory biomarkers and clinical urological practice, aiming to reduce overtreatment of indolent disease while ensuring aggressive cancers receive timely intervention. Her contributions are particularly relevant for clinicians seeking to refine patient selection for radical prostatectomy.
Research Focus
Key Achievements
Top Papers
- 1